Zacks Research Has Positive Outlook for FMS FY2025 Earnings

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) – Equities research analysts at Zacks Research upped their FY2025 earnings per share estimates for Fresenius Medical Care AG & Co. KGaA in a research note issued on Tuesday, November 25th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $2.30 for the year, up from their previous forecast of $2.21. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Fresenius Medical Care AG & Co. KGaA’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Fresenius Medical Care AG & Co. KGaA’s Q4 2025 earnings at $0.70 EPS, Q1 2026 earnings at $0.51 EPS, Q2 2026 earnings at $0.55 EPS, Q3 2026 earnings at $0.68 EPS, FY2026 earnings at $2.43 EPS, Q2 2027 earnings at $0.59 EPS, Q3 2027 earnings at $0.63 EPS and FY2027 earnings at $2.49 EPS.

A number of other brokerages have also recently weighed in on FMS. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. Wall Street Zen cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 8th. Bank of America downgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research report on Wednesday, October 15th. Finally, UBS Group cut Fresenius Medical Care AG & Co. KGaA from a “sell” rating to an “underperform” rating in a research report on Wednesday, October 15th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA has a consensus rating of “Reduce” and an average target price of $30.00.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.9%

Shares of Fresenius Medical Care AG & Co. KGaA stock opened at $23.84 on Thursday. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $21.83 and a 12-month high of $30.46. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 0.44. The stock has a 50 day moving average price of $25.60 and a two-hundred day moving average price of $26.36. The stock has a market capitalization of $13.99 billion, a P/E ratio of 19.54, a PEG ratio of 0.64 and a beta of 0.90.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.05. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The company had revenue of $5.73 billion during the quarter, compared to the consensus estimate of $4.72 billion.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in FMS. Todd Asset Management LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the first quarter worth about $12,009,000. Hennessy Advisors Inc. bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 2nd quarter worth approximately $11,479,000. Millennium Management LLC grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 50.0% during the 1st quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock worth $26,982,000 after purchasing an additional 361,364 shares in the last quarter. Raymond James Financial Inc. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 1,508.1% during the first quarter. Raymond James Financial Inc. now owns 287,751 shares of the company’s stock valued at $7,165,000 after purchasing an additional 269,857 shares during the period. Finally, Bank of America Corp DE increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% during the second quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock valued at $9,637,000 after purchasing an additional 248,477 shares during the period. Institutional investors and hedge funds own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.